OncLive TV

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses studies investigating regorafenib (Stivarga) in metastatic colorectal cancer.

James Mohler, MD, Roswell Park Cancer Institute, explains the progress needed to better understand androgen receptors.

Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of brentuximab vedotin as frontline treatment of systemic anaplastic large cell lymphoma.

Katsuhiko Uesaka, MD, PhD, from the Shizuoka Cancer Center Hospital in Japan, discusses the JASPAC-01 study that compared gemcitabine to S-1 in Asian patients with resected pancreatic cancer.

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's Tyrosine Kinase (BTK) in chronic lymphocytic leukemia.

Hugo Ford, MD, from the Addenbrooke's Hospital in Cambridge, UK, describes results from the phase III COUGAR-02 study that examined second-line docetaxel in patients with advanced gastroesophageal adenocarcinoma.

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, reviews clinical trials that are investigating the optimal adjuvant treatment for patients with breast cancer.

Harry Erba, MD, PhD, discusses the results of a phase II study analyzing azacitidine and gemtuzumab ozogamicin as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 AML.

Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, details the advances in life expectancy for patients with multiple myeloma.

Suresh S. Ramalingam, MD, from Emory University's Winship Cancer Institute, explains that a number of new cytotoxic drugs are being developed in combination with targeted therapies, such as EGFR inhibitors.

William T. DeRosa, DO, from Carol G. Simon Cancer Center at Morristown Memorial Hospital, discusses subset analyses from the phase III CA031 trial that examined nab-paclitaxel in non-small cell lung cancer.

Tal Zaks, MD, PhD, Sanofi Oncology, details a phase II randomized study of the JAK2 inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF.

Richard R. Furman, MD, from the Weill Cornell Medical Center, discusses the safety profile of the oral BTK inhibitor ibrutinib in both relapsed/refractory and treatment naive patients with chronic lymphocytic leukemia.

Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, explains the factors that determine patient tolerability to allogeneic bone marrow transplant.

Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, reviews results from the phase III LEA trial that investigated add-on bevacizumab in breast cancer.

Smita Bhatia, MD, MPH, Population Sciences, City of Hope, Duarte, California, explains a clinical trial analyzing genetic susceptibility to anthracycline-related congestive heart failure in survivors of hematopoietic cell transplantation.

Michelle A. Fanale, MD, from the MD Anderson Cancer Center, discusses a phase I trial that examined the frontline administration of brentuximab vedotin for patients with subtypes of lymphoma.

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute and Brigham and Women's Hospital, discusses trials investigating cabozantinib in breast cancer.

Brian G. M. Durie, MD, Cedars-Sinai Medical Center, Senior Advisor, Hematologic Malignancies, National Program Director, Multiple Myeloma and Related Disorders for Aptium Oncology, discusses novel therapies for multiple myeloma.

David Schuster, MD, director, from Emory University, compares the efficacy of bone scans and FDG-PET/CT scans for detecting bone metastases in patients with breast cancer.

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses the EGFR-targeted tyrosine kinase inhibitor erlotinib for patients with non-small cell lung cancer.

Andrew D. Zelenetz, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, explains the impact that rituximab has made in the treatment of patients with non-Hodgkin and B-cell lymphomas.

Randall F. Holcombe, MD, Tisch Cancer Institute at Mount Sinai Medical Center, speaks about the use of aflibercept in patients with metastatic colorectal cancer.

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined the CDK inhibitor PD 0332991 for women with advanced estrogen receptor-positive breast cancer.

Matthew H.G. Katz, MD, from the MD Anderson Cancer Center, discusses borderline resectable pancreatic ductal adenocarcinoma, a newer stage of pancreatic cancer introduced by the NCCN in 2003.

Srikala Sridhar, MD, MSc, from the University of Toronto, Canada, discusses the results of a single arm phase II trial examining nab-paclitaxel as a secondary treatment for urothelial cancer.

Don S. Dizon, MD, Assistant in Medicine, Medical Gynecologic Oncology, Massachusetts General Hospital, explains the relationship between PTEN mutations and mTOR inhibitors in endometrial cancer.

Francisco Cervantes, MD, PhD, Hospital Clinic, IDIBAPS, Barcelona, Spain, discusses the initial and long-term findings of the COMFORT-II trial of ruxolitib for the treatment of myelofibrosis.

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, discusses the results of a phase III study comparing the efficacy of eribulin mesylate to capecitabine in patients with locally advanced or metastatic breast cancer.